According to the statement, the Envisia classifier is the first commercially available test that could help distinguish IPF from other ILDs, without the need for surgery.
The Envisia classifier recently received Medicare coverage, making it the first test of its kind for improving IPF diagnosis to be covered for the nation's 55 million Medicare patients.
Price: 25.13, Change: +0.06, Percent Change: +0.24
|Market Chatter: JPMorgan Plans on Transferring Euro ...|
|General Motors to Sell Last Factory in India to Grea...|
|Copart (CPRT) Insider Makes Significant Share Sale|
|Insider at Aptinyx (APTX) Makes Significant purchase...|
|Insiders Make Significant Stock Sales in PriceSmart ...|